Whether treatment of hyperglycaemia prevents progression of diabetic nephropathy is controversial. Intensive glycaemic control reduces the risk of microalbuminuria and macroalbuminuria, but there is no clear-cut evidence showing that it reduces doubling of serum creatinine levels or risk of death from kidney disease. Larger studies or further follow-up of previous trials are required to better assess renal outcomes.
This is a preview of subscription content, log in via an institution to check access.
References
DCCT/EDIC Research Group et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 365, 2366–2376 (2011).
Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M. & Parikh, C. R. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 172, 761–769 (2012).
Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643–2653 (2005).
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829–840 (2007).
Zoungas, S. et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care 32, 2068–2074 (2009).
Gaede, P., Vedel, P., Parving, H. H. & Pedersen, O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353, 617–622 (1999).
Zoungas, S. et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55, 636–643 (2012).
Hansen, M. B., Jensen, M. L. & Carstensen, B. Causes of death among diabetic patients in Denmark. Diabetologia 55, 294–302 (2012).
Anavekar, N. S. et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351, 1285–1295 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares that he has received honoraria from Boehringer Ingelheim, Merck and Servier.
Rights and permissions
About this article
Cite this article
Cooper, M. Treating diabetic nephropathy—still an unresolved issue. Nat Rev Endocrinol 8, 515–516 (2012). https://doi.org/10.1038/nrendo.2012.125
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.125
- Springer Nature Limited
This article is cited by
-
Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile
BMC Nephrology (2023)
-
Circ_0000064 knockdown attenuates high glucose-induced proliferation, inflammation and extracellular matrix deposition of mesangial cells through miR-424-5p-mediated WNT2B inhibition in cell models of diabetic nephropathy
Clinical and Experimental Nephrology (2022)
-
Functional Role of SUV39H1 in Human Renal Tubular Epithelial Cells Under High-glucose Ambiance
Inflammation (2018)
-
Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation
Cell Death & Disease (2017)
-
Corosolic acid inhibits the proliferation of glomerular mesangial cells and protects against diabetic renal damage
Scientific Reports (2016)